Theracryf Plc
LSE: TCF.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Huw Jones
- Employees
- 9
- Headquarters
- Nether Alderley, United Kingdom
- IPO year
- 2015
- Market cap
- £4.7M
- Website
- https://theracryf.com
Loading TCF…
Loading profile data…Frequently asked questions about TCF
What does Theracryf Plc (TCF.L) do?
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and...
Where does TCF.L trade?
Theracryf Plc (TCF.L) trades on the London Stock Exchange.
What sector is TCF.L in?
Theracryf Plc (TCF.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Theracryf Plc?
Huw Jones is the chief executive officer of Theracryf Plc (TCF.L).
Where is Theracryf Plc headquartered?
Theracryf Plc is headquartered in United Kingdom.
Does TCF.L pay a dividend?
Theracryf Plc (TCF.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TCF.L go public?
Theracryf Plc (TCF.L) completed its initial public offering in 2015.